Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 8/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.31 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970080 | 1.00 | RBP4 (0.35) | RBP4BTKEIF2AK4PDCD1CD274 | |
| SCHEMBL19970213 | 1.00 | RBP4 (0.35) | RBP4BTKEIF2AK4PDCD1CD274 | |
| SCHEMBL19970020 | 0.98 | RBP4 (0.35) | RBP4BTKEIF2AK4PDCD1CD274 | |
| SCHEMBL19970129 | 0.98 | RBP4 (0.35) | RBP4BTKEIF2AK4PDCD1CD274 | |
| SCHEMBL23770801 | 0.92 | GPBAR1 (0.33) | RBP4BTKPROKR1HSD11B1 | |
| SCHEMBL23770721 | 0.90 | GPBAR1 (0.33) | RBP4BTKPROKR1HSD11B1 | |
| SCHEMBL23770655 | 0.89 | DGAT1 (0.32) | BTKHSD11B1 | |
| SCHEMBL23770875 | 0.89 | BTK (0.34) | BTKEIF2AK4 | |
| SCHEMBL19970083 | 0.89 | BTK (0.34) | BTKEIF2AK4 | |
| SCHEMBL23770690 | 0.89 | DGAT1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | RBP4 3941/4885BTK 235/4885EIF2AK4 3294/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | RBP4 3941/4885BTK 235/4885EIF2AK4 3294/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | RBP4 3941/4885BTK 235/4885EIF2AK4 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.